NLS Pharmaceutics AG (NLSP) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear

NLS Pharmaceutics AG

NASDAQ: NLSP · Real-Time Price · USD
2.00
-0.12 (-5.66%)
At close: Oct 03, 2025, 3:59 PM
1.98
-0.75%
After-hours: Oct 03, 2025, 07:41 PM EDT

NLS Pharmaceutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q4 2024 Q2 2024 Q4 2023 Q2 2023 Q4 2022 Q2 2022 Q4 2021 Q2 2021
Period Ending Dec 31, 2024 Jun 30, 2024 Dec 31, 2023 Jun 30, 2023 Dec 31, 2022 Jun 30, 2022 Dec 31, 2021 Jun 30, 2021
Revenue
n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
-2.38K 5.7K 5.7K 5.7K 5.7K 5.7K 5.03K 5.02K
Gross Profit
2.38K -5.7K -5.7K -5.7K -5.7K -5.7K -5.03K -5.02K
Operating Income
-2.33M -2.05M -4.26M -7.55M -6.79M -8.69M -7.32M -4.54M
Interest Income
n/a n/a n/a 0.13 91.69 9.18 0.00 68.13
Pretax Income
55.02K -2.04M -4.56M -7.61M -7.85M -8.64M -7.34M -4.6M
Net Income
55.02K -2.04M -4.56K -7.61M -7.85M -8.64M -7.34M -4.6M
Selling & General & Admin
1.43M 1.78M 2.73K 3.16M 3.36M 3.14M 3.26M 2.67M
Research & Development
150.7K 271.35K 1.52K 4.38M 3.43M 5.54M 4.06M 1.86M
Other Expenses
743.84K n/a 4.25M n/a n/a n/a n/a n/a
Operating Expenses
2.33M 2.05M 4.26M 7.54M 6.79M 8.68M 7.31M 4.54M
Interest Expense
63.03K 86.98K 145.02K 129.00 91.69K 9.18K n/a 68.13K
Selling & Marketing Expenses
n/a 1.77M n/a 3.16M 3.35M 3.14M 3.25M 2.67M
Cost & Expenses
2.33M 2.05M 4.26M 7.55M 6.79M 8.69M 7.32M 4.54M
Income Tax Expense
n/a n/a n/a -4 -4 -4 0.50 -2
Shares Outstanding (Basic)
55K 41.95M 32.43M 38.18M 26.68M 15.89M 14.75M 11.07M
Shares Outstanding (Diluted)
2.04M 41.95M 32.43M 38.18M 26.68M 15.89M 14.75M 11.07M
EPS (Basic)
-2.63 n/a -0.14 -0.2 -0.29 -0.54 -0.5 -0.42
EPS (Diluted)
-0.99 n/a -0.14 -0.2 -0.29 -0.54 -0.5 -0.42
EBITDA
-1.59M -1.94M -4.41M -7.54M -6.79M -8.68M -7.34M -4.54M
EBIT
-1.58M -1.95M -4.26M -7.55M -6.79M -8.69M -7.32M -4.54M
Depreciation & Amortization
-2.38K 5.7K 5.70 5.7K 5.7K 5.7K 5.03K 5.02K